|
|
|
| home > white papers > Protein Therapeutics - Reading Scientific Services Ltd (RSSL) |
|
|
 WHITE PAPERS |
|
Reading Scientific Services Ltd (RSSL)
|
|
Protein Therapeutics
|
|
The use of protein-based biological materials to treat patients suffering from a wide range of diseases is one of the success stories of modern medicine. The diseases treated include diabetes (insulin), growth hormone deficiencies (recombinant human growth hormone), inborn errors of metabolism (glucosylceramidase, alpha-galactosidase), and red blood cell deficiency (erythropoietin). As the market develops, the number of biopharmaceutical products both being submitted for regulatory approval and reaching the end of their patent life is increasing.
|
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Stability Testing and Forced Degradation Stress Tests - Proactive Risk Management
Whereas the durability of many consumables, have a strong tendency to decrease, stability is and remains a crucial factor for pharmaceuticals. That is why the identification and elimination of factors, which put long-term stability at risk, is central during development – and an important requirement concerning the product’s quality.
More info >> |
|
 |
White Papers |
 |
|
Crunch Time: The Impact of Serialisation Requirements on Packaging Operations
PCI Pharma Services
The deadlines for including unique product identifiers on prescription drugs is putting a strain on multiple parts of the industry, much of which is ill-prepared to meet the target. Here, we look to the experience of a company that is ahead of the curve for lessons on how to manage and ease the transition to serialisation.
More info >> |
|
 |
Industry Events |
 |
Clinical Operations in Oncology Trials West Coast
17-18 November 2020, Hilton San Francisco Airport Bayfront
Clinical Operations in Oncology Trials West Coast will be returning this April for another 2 day event full of thought-provoking presentations, discussions and roundtables. This years' conference highlights include the high-level, interactive immuno-oncology discussion panel where specialists from Shasta Bio Ventures, Abbvie and BeiGene shared their top tips on how to run successful and impactful immuno-oncology studies.
More info >> |
|
|
|
.jpg)
